United Nations Office on Drugs and Crime (2015): World Drug Report 2015 (United Nations publication, Sales No. E.15.XI.6). View in Article

Santacroce R.

Corazza O.

Martinotti G.

Bersani F.S.

Valeriani G.

Di Giannantonio M. Psyclones: A roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products. Hum Psychopharmacol. 30 : 265-271 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Understanding the “Spice” Phenomenon. Publications Office of the European Union , Luxembourg View in Article Google Scholar

Hu X.

Primack B.A.

Barnett T.E.

Cook R.L. College students and use of K2: An emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy. 6. : 16-19 View in Article Google Scholar

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2015): European Drug Report 2015: Trends and Developments. Luxembourg: Publications Office of the European Union. View in Article

Uchiyama N.

Kawamura M.

Kikura-Hanajiri R.

Goda Y. Identification and quantitative analyses of two cannabimimetic phenylacetylindoles, JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles, JWH-081, JWH-015, JWH-200 and JWH-073, as designer drugs in illegal products. Forensic Toxicol. 29 : 25-37 View in Article Scopus (0)

Crossref

Google Scholar

Drug Enforcement Administration, Department of Justice Schedules of controlled substances: Temporary placement of three synthetic cannabinoids into schedule I. Final order. Fed Regist. 80 : 5042-5047 View in Article PubMed

Google Scholar

S. 3190 (112th Congress) (2012): Synthetic Drug Abuse Prevention Act of 2012. Second Session: Addition of synthetic drugs to schedule I of the Controlled Substances Act. View in Article

Wood D.M.

Heyerdahl F.

Yates C.B.

Dines A.M.

Giraudon I.

Hovda K.E.

et al. The European Emergencies Drug Network (Euro-DEN). Clin Toxicol. 52 : 239-241 View in Article Scopus (0)

Crossref

Google Scholar

Teske J.

Weller J.P.

Fieguth A.

Rothämel T.

Schulz Y.

Tröger H.D. Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-018) in human serum by liquid chromatography–tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 878 : 2659-2663 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Gottardo R.

Chiarini A.

Dal Prà I.

Seri C.

Rimondo C.

Serpelloni G.

et al. Direct screening of herbal blends for new synthetic cannabinoids by MALDI-TOF MS. J Mass Spectrom. 47 : 141-146 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Holm N.B.

Pedersen A.J.

Dalsgaard P.W.

Linnet K. Metabolites of 5F-AKB-48, a synthetic cannabinoid receptor agonist, identified in human urine and liver microsomal preparations using liquid chromatography high-resolution mass spectrometry. Drug Test Anal. 7 : 199-206 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Barnes A.J.

Spinelli E.

Young S.

Martin T.M.

Kleete K.L.

Huestis M.A. Validation of an ELISA synthetic cannabinoids urine assay. Ther Drug Monit. 37 : 661-669 View in Article PubMed

Crossref

Google Scholar

Gwak S.

Arroyo-Mora L.E.

Almirall J.R. Qualitative analysis of seized synthetic cannabinoids and synthetic cathinones by gas chromatography triple quadrupole tandem mass spectrometry. Drug Test Anal. 7 : 121-130 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Dhawan J.

Deng H.

Gatley S.J.

Makriyannis A.

Akinfeleye T.

Bruneus M.

et al. Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233. Synapse. 60 : 93-101 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Wiley J.L.

Marusich J.A.

Lefever T.W.

Antonazzo K.R.

Wallgren M.T.

Cortes R.A.

et al. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and potency of novel synthetic cannabinoids in producing Δ9-tetrahydrocannabinol-like effects in mice. J Pharmacol Exp Ther. 354 : 328-339 View in Article PubMed

Crossref

Google Scholar

Monte A.A.

Bronstein A.C.

Cao D.J.

Heard K.J.

Hoppe J.A.

Hoyte C.O.

et al. An outbreak of exposure to a novel synthetic cannabinoid. N Engl J Med. 370 : 389-390 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Makriyannis A, Deng H (2001): Cannabimimetic indole derivatives. US Patent 2005/0119234 A1, assignee University of Connecticut. View in Article Google Scholar

Brents L.K.

Reichard E.E.

Zimmerman S.M.

Moran J.H.

Fantegrossi W.E.

Prather P.L. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 6 : e21917 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Hruba L.

Ginsburg B.C.

McMahon L.R. Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Δ9-tetrahydrocannabinol treatment in rhesus monkeys. J Pharmacol Exp Ther. 342 : 843-849 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Järbe T.U.

Gifford R.S.

Zvonok A.

Makriyannis A. Delta-9-Tetrahydrocannabinol discriminative stimulus effects of AM2201 and related aminoalkylindole analogs in rats [published online ahead of print Sep 21]. Behav Pharmacol. View in Article Google Scholar

Barann M.

Molderings G.

Brüss M.

Bönisch H.

Urban B.W.

Göthert M. Direct inhibition by cannabinoids of human 5-HT3A receptors: Probable involvement of an allosteric modulatory site. Br J Pharmacol. 137 : 589-596 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Zavitsanou K.

Wang H.

Dalton V.S.

Nguyen V. Cannabinoid administration increases 5HT1A receptor binding and mRNA expression in the hippocampus of adult but not adolescent rats. Neuroscience. 169 : 315-324 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Papanti D.

Orsolini L.

Francesconi G.

Schifano F. “Noids” in a nutshell: Everything you (don’t) want to know about synthetic cannabimimetics. Adv Dual Diagn. 7 : 137-148 View in Article Scopus (0)

Crossref

Google Scholar

Demir R.

Leuwer M.

de la Roche J.

Krampfl K.

Foadi N.

Karst M.

et al. Modulation of glycine receptor function by the synthetic cannabinoid HU210. Pharmacology. 83 : 270-274 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Klein T.W.

Lane B.

Newton C.A.

Friedman H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med. 225 : 1-8 View in Article PubMed

Crossref

Google Scholar

Zoppi S.

Madrigal J.L.

Caso J.R.

García-Gutiérrez M.S.

Manzanares J.

Leza J.C.

et al. Regulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice. Br J Pharmacol. 171 : 2814-2826 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Irie T.

Kikura-Hanajiri R.

Usami M.

Uchiyama N.

Goda Y.

Sekino Y. MAM-2201, a synthetic cannabinoid drug of abuse, suppresses the synaptic input to cerebellar Purkinje cells via activation of presynaptic CB1 receptors. Neuropharmacology. 95 : 479-491 View in Article PubMed

Crossref

Google Scholar

Behonick G.

Shanks K.G.

Firchau D.J.

Mathur G.

Lynch C.F.

Nashelsky M.

et al. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol. 38. : 559-562 View in Article Google Scholar

Ibrahim S.

Al-Saffar F.

Wannenburg T. A unique case of cardiac arrest following K2 abuse. Case Rep Cardiol. 2014 : 120607 View in Article PubMed

Crossref

Google Scholar

Gerostamoulos D.

Drummer O.H.

Woodford N.W. Deaths linked to synthetic cannabinoids. Forensic Sci Med Pathol. 11 : 478 View in Article PubMed

Crossref

Google Scholar

Bronstein A.C.

Spyker D.A.

Cantilena Jr, L.R.

Rumack B.H.

Dart R.C. 2011 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila). 50 : 911-1164 View in Article PubMed

Crossref

Google Scholar

Mowry J.B.

Spyker D.A.

Cantilena Jr, L.R.

McMillan N.

Ford M. 2013 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 31st Annual Report. Clin Toxicol (Phila). 52 : 1032-1283 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Chimalakonda K.C.

Seely K.A.

Bratton S.M.

Brents L.K.

Moran C.L.

Endres G.W.

et al. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: Identification of novel cannabinoid receptor ligands. Drug Metab Dispos. 40 : 2174-2184 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Brents L.K.

Gallus-Zawada A.

Radominska-Pandya A.

Vasiljevik T.

Prisinzano T.E.

Fantegrossi W.E.

et al. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol. 83 : 952-961 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Kavanagh P.

Grigoryev A.

Savchuk S.

Mikhura I.

Formanovsky A. UR-144 in products sold via the Internet: Identification of related compounds and characterization of pyrolysis products. Drug Test Anal. 5 : 683-692 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Seely K.A.

Lapoint J.

Moran J.H.

Fattore L. Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry. 39 : 234-243 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Baumann M.H.

Solis Jr, E.

Watterson L.R.

Marusich J.A.

Fantegrossi W.E.

Wiley J.L. Baths salts, spice, and related designer drugs: The science behind the headlines. J Neurosci. 34 : 15150-15158 View in Article PubMed

Crossref

Google Scholar

Winstock A.R.

Barratt M.J. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol. 28 : 390-393 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

de Havenon A.

Chin B.

Thomas K.C.

Afra P. The secret “spice”: An undetectable toxic cause of seizure. Neurohospitalist. 1 : 182-186 View in Article PubMed

Crossref

Google Scholar

Gugelmann H.

Gerona R.

Li C.

Tsutaoka B.

Olson K.R.

Lung D. “Crazy Monkey” poisons man and dog: Human and canine seizures due to PB-22, a novel synthetic cannabinoid. Clin Toxicol (Phila). 52 : 635-638 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Schep L.

Slaughter R.

Hudson S.

Place R.

Watts M. Delayed seizure-like activity following analytically confirmed use of previously unreported synthetic cannabinoid analogues. Hum Exp Toxicol. 34 : 557-560 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Durand D.

Delgado L.L.

de la Parra-Pellot D.M.

Nichols-Vinueza D. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: A case report. Clin Schizophr Relat Psychoses. 8 : 205-208 View in Article Scopus (12)

PubMed

Crossref

Google Scholar

Möller I.

Wintermeyer A.

Bender K.

Jübner M.

Thomas A.

Krug O.

et al. Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test Anal. 3 : 609-620 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Papanti D.

Schifano F.

Botteon G.

Bertossi F.

Mannix J.

Vidoni D.

et al. “Spiceophrenia”: A systematic overview of “spice”-related psychopathological issues and a case report. Hum Psychopharmacol. 28 : 379-389 View in Article Scopus (57)

PubMed

Crossref

Google Scholar

Dresen S.

Kneisel S.

Weinmann W.

Zimmermann R.

Auwärter V. Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J Mass Spectrom. 46 : 163-171 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Zimmermann U.S.

Winkelmann P.R.

Pilhatsch M.

Nees J.A.

Spanagel R.

Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of “spice gold”. Dtsch Artzebl Int. 106 : 464-467 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

McQuade D.

Hudson S.

Dargan P.I.

Wood D.M. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol. 69 : 373-376 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Thomas S.

Bliss S.

Malik M. Suicidal ideation and self-harm following K2 use. J Okla State Med Assoc. 105 : 430-433 View in Article PubMed

Google Scholar

Aksel G.

Güneysel Ö.

Taşyürek T.

Kozan E.

Çevik Ş.E. Intravenous lipid emulsion therapy for acute synthetic cannabinoid intoxication: Clinical experience in four cases. Case Rep Emerg Med. 2015 : 180921 View in Article PubMed

Google Scholar

Radhakrishnan R.

Addy P.H.

Sewell R.A.

Skosnik P.D.

Ranganthan M.

D’Souza D.C. Cannabis, cannabinoids, and the association with psychosis. in: Madras B. Kuhar M.J. The Effects of Drug Abuse on the Human Nervous System. Neuroscience-Net, LLC , View in Article Google Scholar

Wilkinson S.T.

Radhakrishnan R.

D’Souza D.C. Impact of cannabis use on the development of psychotic disorders. Curr Addict Rep. 1. : 115-128 View in Article Google Scholar

Ben Amar M.

Potvin S. Cannabis and psychosis: What is the link?. J Psychoactive Drugs. 39 : 131-142 View in Article PubMed

Crossref

Google Scholar

van Amsterdam J.

Brunt T.

van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol. 29 : 254-263 View in Article Scopus (31)

PubMed

Crossref

Google Scholar

Glue P.

Al-Shaqsi S.

Hancock D.

Gale C.

Strong B.

Schep L. Hospitalization associated with use of the synthetic cannabinoid K2. N Z Med J. 126 : 18-23 View in Article PubMed

Google Scholar

Johns L.C.

Cannon M.

Singleton N.

Murray R.M.

Farrell M.

Brugha T.

et al. Prevalence and correlates of self-reported psychotic symptoms in the British population. Br J Psychiatry. 185 : 298-305 View in Article Scopus (307)

PubMed

Crossref

Google Scholar

Smith D.L.

Roberts C. Synthetic marijuana use and development of catatonia in a 17-year-old male. Minn Med. 97 : 38 View in Article Google Scholar

Berry-Cabán C.S.

Kleinschmidt P.E.

Rao D.S.

Jenkins J. Synthetic cannabinoid and cathinone use among US soldiers. US Army Med Dep J. : 19-24 View in Article PubMed

Google Scholar

Berry-Cabán C.S.

Slack L.A.

Huffman C.A.

Whitecar P.W.

Haley C. Synthetic cannabinoid and synthetic cocaine use during pregnancy in a soldier. J Subst Abuse Alcohol. 1 : 1002-1004 View in Article Google Scholar

Tung C.K.

Chiang T.P.

Lam M. Acute mental disturbance caused by synthetic cannabinoid: A potential emerging substance of abuse in Hong Kong. East Asian Arch Psychiatry. 22 : 31-33 View in Article PubMed

Google Scholar

Di Forti M.

Sallis H.

Allegri F.

Trotta A.

Ferraro L.

Stilo S.A.

et al. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull. 40 : 1509-1517 View in Article Scopus (66)

PubMed

Crossref

Google Scholar

Atwood B.K.

Huffman J.

Straiker A.

Mackie K. JWH018, a common constituent of “Spice” herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol. 160 : 585-593 View in Article Scopus (128)

PubMed

Crossref

Google Scholar

Rosenbaum C.D.

Carreiro S.P.

Babu K.M. Here today, gone tomorrow … and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol. 8 : 15-32 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Wintermeyer A.

Möller I.

Thevis M.

Jübner M.

Beike J.

Rothschild M.A.

et al. In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal Bioanal Chem. 398 : 2141-2153 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Brents L.K.

Reichard E.E.

Zimmerman S.M.

Moran J.H.

Fantegrossi W.E.

Prather P.L. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One. 6 : e21917 View in Article Scopus (0)

PubMed

Crossref

Google Scholar

Wegener N.

Koch M. Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Res. 1253 : 81-91 View in Article Scopus (54)

PubMed

Crossref

Google Scholar

Leweke F.M.

Piomelli D.

Pahlisch F.

Muhl D.

Gerth C.W.

Hoyer C.

et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2 : e94 View in Article Scopus (162)

PubMed

Crossref

Google Scholar